No Data
No Data
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Foghorn Therapeutics: Holding for FHD-286 Clinical Trial Outcomes and Financial Position Analysis
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
Express News | Deerfield Mgmt, L.p Reports 5.31% Passive Stake in Foghorn Therapeutics as of Sept 13 - SEC Filing
Foghorn Therapeutics Executive Sells Over $107k in Company Stock
loading...